Skip to main content

Table 1 Demographic, anthropometric, and reproductive features in the two groups at the time of entering the study

From: Metformin as a new option in the medical management of breast fibroadenoma; a randomized clinical trial

Variables

Metformin Group

(n = 83)

Placebo Group

(n = 92)

p-value

Age

39.90 ± 10.54

39.42 ± 10.14

0.76a

Body mass Index (BMI)

25.51 ± 4.72

26.36 ± 6.95

0.35a

Waist/hip ratio

0.86 ± 0.07

0.86 ± 0.13

0.75a

Age of menarche

13.13 ± 1.33

13.32 ± 1.39

0.37a

Parity

1.53 ± 1.13

1.51 ± 1.10

0.91a

Age at first delivery

16.99 ± 11.12

18.35 ± 10.73

0.41a

History of twin pregnancy

2 (2.4)

4 (4.3)

0.48b

History of abortion

0.45 ± 0.80

0.25 ± 0.59

0.07a

History of breastfeeding

60 (72.3)

70 (76.1)

0.57b

History of Infertility

7 (8.4)

7 (7.7)

1b

History of PCO

4 (4.8)

2 (2.2)

0.34b

History of OCP use

25 (30.1)

26 (28.3)

0.79b

History of HRT use

6 (7.2)

5 (5.4)

0.52b

  1. a Independent Student t-test. b Chi-square test. PCO polycystic ovarian disease, OCP oral contraceptive, HRT hormone replacement therapy